v3.26.1
Statements of Changes in Stockholders’ Equity - USD ($)
Preferred Stock
Common Stock
Treasury Stock
Additionalb Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Total
Balance at Dec. 31, 2023 $ 45 $ (172) $ 69,105,176 $ 840 $ (59,364,812) $ 9,741,077
Balance (in Shares) at Dec. 31, 2023 454,169          
Balance (in Shares) at Dec. 31, 2023     1,550        
Stock-based compensation expense 101,844 101,844
Vesting of restricted stock 147,831 147,831
Vesting of restricted stock (in Shares)   1,958          
Repurchase of common stock exercisable under PIPE Warrants (52,500) (52,500)
Issuance of common stock $ 13 398,429 398,442
Issuance of common stock (in Shares)   132,814          
Issuance of common stock in connection with At The Market Offering Agreement $ 20 1,494,394 1,494,414
Issuance of common stock in connection with At The Market Offering Agreement (in Shares)   199,004          
Issuance of common stock through exercise of warrants $ 74 4,599,948 4,600,022
Issuance of common stock through exercise of warrants (in Shares)   734,221          
Offering costs in connection with At The Market Offering Agreement (255,288) (255,288)
Offering costs in connection with issuance of common shares and warrants (366,189) (366,189)
Unrealized loss on available-for-sale securities (840) (840)
Reverse stock split adjustment $ 18 (18)
Reverse stock split adjustment (in Shares)   174,738          
Net loss (12,497,805) (12,497,805)
Balance at Dec. 31, 2024 $ 170 $ (172) 75,173,627 (71,862,617) $ 3,311,008
Balance (in Shares) at Dec. 31, 2024 1,696,904         1,696,904
Balance at (in Shares) at Dec. 31, 2024     1,550       1,550
Stock-based compensation expense 1,338 $ 1,338
Vesting of restricted stock 19,928 19,928
Vesting of restricted stock (in Shares)   400          
Issuance of common stock in connection with Underwritten financing $ 148 1,037,702 1,037,850
Issuance of common stock in connection with Underwritten financing (in Shares)   1,482,644          
Issuance of common stock in connection with PIPE financing $ 27 299,972 299,999
Issuance of common stock in connection with PIPE financing (in Shares)   267,379          
Issuance of common stock through exercise of prefunded warrants $ 632 4,411,091 4,411,723
Issuance of common stock through exercise of prefunded warrants (in Shares)   6,323,719          
Issuance of Series C convertible preferred stock in connection with PIPE financing $ 1 5,499,999 5,500,000
Issuance of Series C convertible preferred stock in connection with PIPE financing (in Shares) 6,875            
Offering costs in connection with the completion of financings (1,006,083) (1,006,083)
Reversal of issued common stock through exercise of prefunded warrants due to error on issuance $ (129) 129
Reversal of issued common stock through exercise of prefunded warrants due to error on issuance (in Shares)   (1,292,449)          
Net loss (10,487,532) (10,487,532)
Balance at Dec. 31, 2025 $ 1 $ 848 $ (172) $ 85,437,703 $ (82,350,149) $ 3,088,231
Balance (in Shares) at Dec. 31, 2025 6,875 8,478,597         8,478,597
Balance at (in Shares) at Dec. 31, 2025     1,550       1,550